摘要
目的 探讨不同分子亚型浸润性乳腺癌的治疗后生存情况.方法 采用回顾性分析,收集2000年1月至201 1年7月在北京肿瘤医院乳腺癌预防治疗中心确诊并在本院完成治疗4491例浸润性乳腺癌病例,根据病例的激素受体状态（HR）、人类表皮生长因子受体2（HER2）的免疫组织化学结果（HER2＋＋的患者进行了FISH检测）,将所有病例分为：HR ＋/HER2-、HER2阳性及HR-/HER2-3个亚型,分析不同分子亚型乳腺癌治疗后生存情况,并分析各分子亚型在不同淋巴结状态下的生存情况.结果 HR ＋/HER2-（2504例）、HER2阳性（680例）及HR-/HER2-型（1085例）的3年无复发生存（RFS）率分别为94.9％、89.5％与92.3％,生存曲线之间的差异有统计学意义,P =0.0001;淋巴结阳性与淋巴结阴性的3年RFS率分别为87.1％与97.8％,生存曲线之间的差异有统计学意义,P＜0.01;淋巴结阴性组3种亚型的乳腺癌RFS生存曲线间的差异无统计学意义,P =0.102;而在淋巴结阳性组HR ＋/HER2-型的RFS明显优于HR-/HER2-型与HER-2阳性型,生存曲线之间的差异有统计学意义,P =0.001.结论 不同分子亚型乳腺癌的治疗后生存情况不同,淋巴结状态可能是更重要的影响因素.
Objective To explore the survival status after treatment for patients with different molecular subtypes of breast cancers.Methods A total of 4491 patients with invasive breast cancer from January 2000 to July 2011 were retrospectively recruited to receive pathological verification and treatment at our clinic.According to the immunohistochemical results of hormone receptor （HR） and human epidermal growth factor receptor 2 （HER2）,they were assigned into 3 groups of HR ＋/HER2-,HER2 ＋ and HR-/ HER2-.Survival analyses were conducted to examine the effects of molecular subtypes and lymph node status on survival.Results The 3-year recurrence free survival for HR ＋/HER2-,HER2 ＋ and HR-/ HER2-were 94.9%,89.5% ane 92.3% respectively.Different molecular subtypes presented different survival patterns （P =0.0001）.The 3-year recurrence-free survival （RFS） for LN ＋ and LN-was 87.1% and 97.8% respectively.And statistical difference existed （P 〈 0.01）.No difference was detected among three molecular subtypes of LN-（P =0.102） ; However,for LN ＋ patients,HR ＋/HER2-showed a higher RFS than HER2 ＋ and HR-/HER2 （P =0.001）.Conclusion Different molecular subtypes of breast cancers have varying survival.And lymph node status is probably an important prognostic factor.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第46期3663-3666,共4页
National Medical Journal of China
关键词
乳腺肿瘤
分子亚型
生存
受体
淋巴结
Breast neoplasms
Molecular subtypes
Survival
Receptor
Lymph nodes
